Abstract IA002: Overcoming the K-Ras inhibitor resistant cell state in PDAC with molecular glues.

IF 5.3 2区医学 Q1 ONCOLOGY

Molecular Cancer Therapeutics Pub Date : 2024-06-10 DOI:10.1158/1538-8514.synthleth24-ia002

F. Ferguson

引用次数: 0

Abstract

K-Ras inhibitor resistance in PDAC is associated with metabolic reprogramming towards a high OXPHOS state. Existing inhibitors of components of the electron transport chain have on-target toxicities that limit their use in the clinic, highlighting an opportunity to develop mechanistically orthogonal approaches. In this talk, I discuss our development of molecular glue degraders that target metabolic vulnerabilities in K-Ras inhibitor resistant PDAC. Citation Format: Fleur M. Ferguson. Overcoming the K-Ras inhibitor resistant cell state in PDAC with molecular glues [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr IA002.

查看原文本刊更多论文

摘要 IA002：用分子胶克服 PDAC 中 K-Ras 抑制剂耐药细胞的状态。

PDAC对K-Ras抑制剂的耐药性与新陈代谢重编程为高OXPHOS状态有关。现有的电子传递链成分抑制剂具有靶向毒性，这限制了它们在临床上的应用，突出了开发机制正交方法的机会。在本讲座中，我将讨论我们针对 K-Ras 抑制剂耐药的 PDAC 的代谢弱点开发的分子胶降解剂。引用格式：Fleur M. Ferguson.用分子胶克服 PDAC 中 K-Ras 抑制剂耐药的细胞状态 [摘要].In：AACR 癌症研究特别会议论文集：扩展和转化癌症合成脆弱性；2024 年 6 月 10-13 日；加拿大魁北克省蒙特利尔。费城（宾夕法尼亚州）：AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr IA002.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Cancer Therapeutics 医学-肿瘤学

CiteScore

11.20

自引率

1.80%

发文量

331

审稿时长

3 months

期刊介绍： Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.